Education
About Us
Working with TipRanks
Follow Us
Filana Therapeutics, Inc. (FLNA)
NASDAQ:FLNA
Total Valuation
Filana Therapeutics has a market cap or net worth of $96.13M. The enterprise value is $5.46M.
Market Cap$96.13M
Enterprise Value$5.46M
Share Statistics
Filana Therapeutics has 48,307,896 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,307,896
Owned by Insiders2.05%
Owned by Institutions1.22%
Financial Efficiency
Filana Therapeutics’s return on equity (ROE) is -1.22 and return on invested capital (ROIC) is -128.00%.
Return on Equity (ROE)-1.22
Return on Assets (ROA)-0.77
Return on Invested Capital (ROIC)-128.00%
Return on Capital Employed (ROCE)-1.28
Revenue Per Employee0.00
Profits Per Employee-3.03M
Employee Count30
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Filana Therapeutics is ―. Filana Therapeutics’s PEG ratio is -0.00413.
PE Ratio―
PS Ratio0.00
PB Ratio1.29
Price to Fair Value1.29
Price to FCF-2.91
Price to Operating Cash Flow-3.13
PEG Ratio-0.00413
Income Statement
In the last 12 months, Filana Therapeutics had revenue of 0.00 and earned -90.97M in profits. Earnings per share was -1.88.
Revenue0.00
Gross Profit0.00
Operating Income-95.39M
Pretax Income-90.97M
Net Income-90.97M
EBITDA-95.39M
Earnings Per Share (EPS)-1.88
Cash Flow
In the last 12 months, operating cash flow was -32.25M and capital expenditures -581.00K, giving a free cash flow of -32.83M billion.
Operating Cash Flow-32.25M
Free Cash Flow-32.83M
Free Cash Flow per Share-0.68
Dividends & Yields
Filana Therapeutics pays an annual dividend of $5.25, resulting in a dividend yield of ―
Dividend Per Share$5.25
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.82
52-Week Price Change-28.42%
50-Day Moving Average2.12
200-Day Moving Average2.51
Relative Strength Index (RSI)44.13
Average Volume (3m)699.70K
Important Dates
Filana Therapeutics upcoming earnings date is May 6, 2026, TBA (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 6, 2026
Ex-Dividend Date―
Financial Position
Filana Therapeutics as a current ratio of 2.23, with Debt / Equity ratio of 0.00%
Current Ratio2.23
Quick Ratio2.23
Debt to Market Cap0.00
Net Debt to EBITDA1.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Filana Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Filana Therapeutics EV to EBITDA ratio is >-0.01, with an EV/FCF ratio of >-0.01.
EV to Sales0.00
EV to EBITDA>-0.01
EV to Free Cash Flow>-0.01
EV to Operating Cash Flow>-0.01
Balance Sheet
Filana Therapeutics has $95.50M in cash and marketable securities with $0.00 in debt, giving a net cash position of $95.50M billion.
Cash & Marketable Securities$95.50M
Total Debt$0.00
Net Cash$95.50M
Net Cash Per Share$1.98
Tangible Book Value Per Share$1.54
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Filana Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-505.96%